TABLE 1.

Select Clinical PRIT and Targeted Radiotherapy Studies with Emphasis on Dosimetry

Year	Vehicle	TRT type	No. of steps	Antigen targets	Tumor types	No. of patients	RIT/PRIT radiocarrier	Administered activity	cGy/37 MBq to tumor	TI			Reference
Year	Vehicle	TRT type	No. of steps	Antigen targets	Tumor types	No. of patients	RIT/PRIT radiocarrier	Administered activity	cGy/37 MBq to tumor	Marrow	Kidney	Liver	Reference
1997	IgG–biotin	PRIT	5^*	CEA, TAG-72, tenascin	Advanced metastatic (breast, brain, colon)	11	⁹⁰Y-biotin	1.85–5.55 GBq	15.2 ± 8.7	13.8	3.4	10.1	(29)
1997	IgG	RIT	1	TAG-72	Metastatic gastrointestinal tract carcinomas	12	⁹⁰Y-IgG	0.640–1.421 GBq	34.5 ± 24.6 (7.0–80.9)	15.2 (3.6–42.1)	ND	0.9 (0.3–1.5)	(45)
1998	mAb– streptavidin	PRIT	3	Epcam	Various^†	40	⁹⁰Y-biotin	2.035–10.693 GBq (0.925–5.18 GBq/m²)	16.4 ± 13.2	48.2	1.43	5.47	(40,42)
1999	IgG–biotin	PRIT	5^*	Tenascin	High-grade glioma	48	⁹⁰Y-biotin	2.22–2.96 GBq/m²	15.20 ± 8.70	19.0	5.63	10.1	(31)
1999	F(ab)′ × F(ab)′	PRIT	2	CEA	MTC	26	¹³¹I-diDTPA(indium)- hapten	0.888–2.22 GBq/m² (1.41–4.14 GBq)	44.33 ± 53.39 (2.91–184)	29.62 ± 35.32	8.36 ± 10.02	10.86 ± 13.55	(71)
2000	mAb– streptavidin	PRIT	3	CD20	Non-Hodgkin lymphoma	7	⁹⁰Y-biotin	1.11 or 1.85 GBq/m²	29 ± 23	181	5.8	18	(41)
2004	(scFv)₄– streptavidin	PRIT	3	CD20	Non-Hodgkin lymphoma	15	⁹⁰Y-biotin	0.555 GBq/m²	26 ± 4 (2–69)	104	3.4	22	(57)
2005	(scFv)₄– streptavidin	PRIT	3	TAG-72	Metastatic CRC	9	⁹⁰Y-biotin	0.37 GBq/m²	28.9 (4.18–121.6)	117.4 (25.8–399.1)	4.12	8.0 (1.9–17.6)	(46)
2014	DNL	PRIT	2	CEA	Metastatic CRC	20	¹⁷⁷Lu-IMP288	2.5–7.4 GBq	ND^‡	¹⁷⁷Lu: 4.68 (0.68–10.91); simulated ⁹⁰Y: 5.41 (0.99–13.72)	ND	ND	(110)

↵* IgG-biotin/avidin chase/streptavidin/biotinylated albumin CA/⁹⁰Y-biotin.
↵^† Refractory epithelial (including ovary, colon, prostate, breast).
↵^‡ Not reported as cGy/37 MBq, but based on absorbed doses to tumor determined using Monte Carlo-based 3D-RD dosimetry package (0.46–4.52 Gy) and corresponding administered activities (5.6 and 2.5 GBq for 0.46 and 4.52 Gy, respectively), range of 0.30–6.69 cGy/37 MBq was calculated.
TRT = targeted radiotherapy; RIT = radioimmunotherapy; ND = not determined.
↵All treatments were administered intravenously.